Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Reports Mild Uptick in Q2 Revenues, Narrowed Losses on Decreased R&D Costs

Click  here to read an updated version of this article.

NEW YORK, Aug. 8 (GenomeWeb News) - Sequenom reported today a slight increase in second-quarter revenues as losses slid sharply on lower costs.

 

The company reported a rise in second-quarter revenues to $6.2 million, versus $6 million in the year-ago quarter, an increase the company attributed to both the addition of new customers and the upgrading of the firm's analysis systems by existing customers.

 

Sequenom's research and development spending dropped to about $3 million in the quarter from $5.7 million a year earlier.

 

The company posted a net loss of $6 million, or $.15 per share, versus a year-ago loss of $9.8 million, or $.25 per share.

As of June 30, Sequenom had cash, cash equivalents, short-term investments, and restricted cash totaling $25.4 million.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.